NO953353D0 - Xantinderivater som adenosin-A -reseptorantagonister - Google Patents
Xantinderivater som adenosin-A -reseptorantagonisterInfo
- Publication number
- NO953353D0 NO953353D0 NO953353A NO953353A NO953353D0 NO 953353 D0 NO953353 D0 NO 953353D0 NO 953353 A NO953353 A NO 953353A NO 953353 A NO953353 A NO 953353A NO 953353 D0 NO953353 D0 NO 953353D0
- Authority
- NO
- Norway
- Prior art keywords
- adenosine
- pct
- receptor antagonists
- xanthine derivatives
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 | |
| PCT/US1994/001009 WO1994019349A1 (en) | 1993-02-26 | 1994-01-27 | Xanthine derivatives as adenosine a1 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953353D0 true NO953353D0 (no) | 1995-08-25 |
| NO953353L NO953353L (no) | 1995-08-25 |
| NO311920B1 NO311920B1 (no) | 2002-02-18 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19953353A NO311920B1 (no) | 1993-02-26 | 1995-08-25 | Xantinderivater som adenosin-A1-reseptorantagonister |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (no) |
| EP (1) | EP0686155B1 (no) |
| JP (1) | JPH08512281A (no) |
| KR (1) | KR100315898B1 (no) |
| CN (1) | CN1041418C (no) |
| AT (1) | ATE169019T1 (no) |
| AU (1) | AU680241B2 (no) |
| CA (1) | CA2155130C (no) |
| DE (1) | DE69412073T2 (no) |
| DK (1) | DK0686155T3 (no) |
| ES (1) | ES2120025T3 (no) |
| HU (1) | HUT72677A (no) |
| IL (1) | IL108750A (no) |
| MX (1) | MX9401406A (no) |
| NO (1) | NO311920B1 (no) |
| NZ (1) | NZ262984A (no) |
| TW (1) | TW261532B (no) |
| WO (1) | WO1994019349A1 (no) |
| ZA (1) | ZA941176B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (fr) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Medicaments pour la prevention et la therapie de l'hyperphosphatemie |
| IL139787A0 (en) | 1998-06-02 | 2002-02-10 | Osi Pharm Inc | PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| DK1450811T3 (da) | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| US6794515B2 (en) * | 2002-05-15 | 2004-09-21 | Genzyme Corporation | Synthesis of 2-alkylcysteine via substituted thiazoline amide |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| EP1709966A4 (en) * | 2003-12-09 | 2009-04-29 | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION | |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007095161A2 (en) * | 2006-02-14 | 2007-08-23 | New York University | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0686155B1 (en) | 1998-07-29 |
| IL108750A0 (en) | 1994-05-30 |
| IL108750A (en) | 2000-09-28 |
| WO1994019349A1 (en) | 1994-09-01 |
| US5840729A (en) | 1998-11-24 |
| DK0686155T3 (da) | 1999-02-01 |
| MX9401406A (es) | 1994-08-31 |
| CA2155130C (en) | 1994-09-01 |
| NZ262984A (en) | 1997-05-26 |
| JPH08512281A (ja) | 1996-12-24 |
| TW261532B (no) | 1995-11-01 |
| AU6296894A (en) | 1994-09-14 |
| ES2120025T3 (es) | 1998-10-16 |
| KR100315898B1 (ko) | 2002-02-28 |
| CN1041418C (zh) | 1998-12-30 |
| HUT72677A (en) | 1996-05-28 |
| DE69412073D1 (de) | 1998-09-03 |
| CN1118599A (zh) | 1996-03-13 |
| DE69412073T2 (de) | 1999-02-18 |
| NO953353L (no) | 1995-08-25 |
| CA2155130A1 (en) | 1994-09-01 |
| ZA941176B (en) | 1994-09-20 |
| NO311920B1 (no) | 2002-02-18 |
| ATE169019T1 (de) | 1998-08-15 |
| HU9502495D0 (en) | 1995-10-30 |
| EP0686155A1 (en) | 1995-12-13 |
| AU680241B2 (en) | 1997-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69622031T2 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| DE69327536T2 (de) | Fibrinogenrezeptor-antagonisten | |
| NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
| DK0687268T3 (da) | Spiroazacykliske derivater som substans P-antagonister | |
| ES2091689T3 (es) | Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos. | |
| ATE235470T1 (de) | Gastrin- und cck-antagonisten | |
| DE69611377T2 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| ES2121193T3 (es) | Derivados de bencimidazoles. | |
| NO953353L (no) | Xantinderivater som adenosin-A -reseptorantagonister | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| ATE113056T1 (de) | Künstliche rezeptor-analoge. | |
| ATE189894T1 (de) | Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel | |
| ES2162078T3 (es) | Compuestos terapeuticos. | |
| GR3024854T3 (en) | Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances. | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| KR960700053A (ko) | 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer) | |
| ITMI950956A0 (it) | Uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca | |
| ATE221068T1 (de) | Anellierte beta-carboline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |